Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.36 |
| ▸ | KIF11 | P52732 | 7/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.34 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.34 |
| ▸ | GHSR | Q92847 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CKS1B | P61024 | 1/20 | 0.32 |
| ▸ | SKP1 | P63208 | 1/20 | 0.32 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18291881 | 0.87 | CA14 (0.41) | CA14L3MBTL1KIF11HDAC3HDAC1 | |
| SCHEMBL45876 | 0.86 | MEN1 (0.41) | CA14L3MBTL1KIF11HDAC3HDAC1 | |
| SCHEMBL16141285 | 0.86 | CA14 (0.45) | CA14L3MBTL1KIF11HDAC3HDAC1 | |
| SCHEMBL14708941 | 0.84 | CA14 (0.45) | CA14L3MBTL1KIF11HDAC3HDAC1 | |
| SCHEMBL12917526 | 0.83 | CA14 (0.39) | CA14L3MBTL1KIF11HDAC3HDAC1 | |
| SCHEMBL16330568 | 0.81 | HDAC3 (0.40) | CA14L3MBTL1KIF11HDAC3HDAC1 | |
| SCHEMBL12917528 | 0.80 | KIF11 (0.46) | KIF11 | |
| SCHEMBL18291847 | 0.79 | CA14 (0.36) | CA14L3MBTL1HDAC3HDAC1HDAC2 | |
| SCHEMBL17493273 | 0.78 | CA14 (0.41) | CA14L3MBTL1KIF11HDAC3HDAC1 | |
| SCHEMBL17080678 | 0.77 | MGLL (0.46) | CA14L3MBTL1GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9561287-B2 | Carrier-linked treprostinil prodrugs | ASCENDIS PHARMA A/S (DK) | 2017-02-07 | — | — | US | disclosed |
| US-20140303245-A1 | Sustained Release Composition of Prostacyclin | ASCENDIS PHARMA A/S (DE) | 2014-10-09 | — | — | US | disclosed |
| US-20140296150-A1 | Carrier-Linked Treprostinil Prodrugs | ASCENDIS PHARMA A/S (DK) | 2014-10-02 | — | — | US | disclosed |
| WO-2013160340-A1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA A/S (DK) | 2013-10-31 | — | — | WO | disclosed |
| WO-2013024051-A1 | SUSTAINED RELEASE COMPOSITION OF PROSTACYCLIN | ASCENDIS PHARMA A/S (DK) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013024052-A1 | CARRIER-LINKED TREPROSTINIL PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296150-A1 | Carrier-Linked Treprostinil Prodrugs | PAH, TK1, SLC16A1 | CA14 1202/4885L3MBTL1 4254/4885KIF11 1524/4885 |
| US-20140303245-A1 | Sustained Release Composition of Prostacyclin | PTGIR, PTGIS, PTGS1 | CA14 3504/4885L3MBTL1 4827/4885KIF11 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.